Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Biomaterials. 2020 Feb 19;241:119858. doi: 10.1016/j.biomaterials.2020.119858

Fig. 4.

Fig. 4.

Biodistribution of 177Lu-DOTA-αMSH-PEG-Cy5-C’ dots in (a-b) M21 and (c-d) B16F10 tumor bearing mice (n=4) at 4 h, 24 h and 96 h post injection reported as injected dose per gram of tissue (% ID/g). Clearance of radioactivity in the urine was reported as percent injected dose (% ID). A blocking study was performed by co-injecting 177Lu-DOTA-αMSH-PEG-Cy5-C’ dots + 5μg of NDP (inserts). The blocking study was performed at the time point of maximum 177Lu-DOTA-αMSH-PEG-Cy5-C’ dot uptake. Excreted activity is defined as that measured in urine at 4 h and in urine plus feces at 24 h and 96 h.